Abstract
Data on the use of intravenous granisetron (Kytril) were collected during a surveillance exercise amongst Swiss oncologists. The data were analysed to ascertain how granisetron was used, and to document the incidence of adverse experiences in a clinical setting. Forty-nine oncologists at 40 Swiss centres were surveyed for their use of granisetron for the prevention and treatment of chemotherapy-induced nausea and vomiting. All were advised to follow the Swiss prescribing instructions for granisetron. They were invited to return data on patient demography, chemotherapy duration, granisetron dosing and adverse experiences. From 285 patients it was deduced that the mean daily dose of granisetron was 1.3 ampoules (3.9 mg) and the median daily dose was 1 ampoule (3 mg). The average number of doses of granisetron per patient per session was 3.8. There were 44 reports of adverse experiences by 34 patients, the most common report being headache. The survey confirmed that the large majority of patients undergoing chemotherapy required only a single dose of granisetron per day, and that the adverse experience profile was good.
References
Bremer K (1992) A single-blind comparative study of the efficacy and safety of intravenous granisetron compared with alizapride plus dexamethasone in the prophylaxis and control of emesis in patients receiving cytostatic therapy over a 5 day, treatment period. Eur J Cancer 28A:1018–1022
Chevalier B, on behalf of the Granistron Study Group (1993) The control of acute cisplatin induced emesis — a comparative study of granisetron and a combination regimen of highdose metoclopramide and dexamethasone. Br J Cancer 68:176–180
Gralla RJ, Itri LM, Pisko SE et al (1981) Antiemetic efficacy of highdose metoclopramide: randomised trials with placebo and prochloperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305:905–909
Kirchner V, Aapro MS, Terrey J-P (1993) Efficacité antiémetique du granisetron: expérience en Suisse. Méd Hyg 51:1510–1514
Lazlo J, Lucas VS (1981) Emesis as a critical problem in chemotherapy. N Engl J Med 305:948–949
Marty M, on behalf of the Granisetron Study Group (1992) A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic induced emesis. Eur J Cancer 28A [Suppl 1]:S12–16
Miner WD, Sanger GJ (1986) Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 88:497–499
Smith I, on behalf of the Granisetron Study Group (1993) A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. J Cancer Res Clin Oncol 119:350–354
Terrey J-P, Zimmermann A, Stauffer S, et al (1993) An observation on the use of Kytril (granisetron) in clinical practice in Switzerland. Eur J Cancer 29A [Suppl 6] poster 1165
Author information
Authors and Affiliations
Additional information
The data in this article were reported in part as a poster presentation to the 7th ECCO meeting Jerusalem, 1993
Rights and permissions
About this article
Cite this article
Terrey, J.P., Casey, P.A. Granisetron (Kytril): a survey of use in clinical practice in Switzerland. Support Care Cancer 3, 435–438 (1995). https://doi.org/10.1007/BF00364988
Issue Date:
DOI: https://doi.org/10.1007/BF00364988